A Phase 1 interventional study of Open Label LAM-003 in Oncology and Acute Myeloid Leukemia, sponsored by OrphAI Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.
Sponsored by OrphAI Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.
Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,394th largest by enrollment of the 1,908 interventional ones that give a count, is one of 99 that started in 2018, is one of 772 in phase 1, and was the 1,429th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:
Uma Borate · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,078 · Phase 2 971 · Phase 3 139 · Phase 4 7
First in 1986; this study’s year is marked. 99 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 35 across the 1,908 interventional studies, 98 across the 126 observational. Of the 1,558 that completed or were terminated, 709 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
574 of 2,138 have an industry lead sponsor. The 10 most frequent:
OrphAI Therapeutics is the lead sponsor of 4 studies on the registry; none are open to participants now.
OrphAI Therapeutics has 1 study filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
168 of the studies in Leukemia, Myeloid, Acute with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT03121014University of Illinois at ChicagoStudy of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes | 2026-11 |
Add all 168 to your calendar (.ics) → With an account.
Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia
This clinical trial is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of LAM-003 across a range of LAM-003 dose levels when administered to subjects with previously treated relapsed or refractory cute Myeloid Leukemia (AML).
Subjects will self-administer oral LAM-003 either once or twice per day as long as they are safely benefitting from therapy. Cohorts of 3 to 6 subjects will be sequentially enrolled at progressively higher dose levels of LAM-003 using a standard 3+3 dose-escalation design. Based on the pattern of dose-limiting toxicities observed in the first 4 weeks of therapy, escalation will proceed to define a recommended LAM-003 dosing regimen.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
This study's enrollment of 17 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →OrphAI Therapeutics is the lead sponsor of 4 studies on the registry; none are open to participants now.
Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label LAM-003 at three sequentially increasing starting dose levels of 200, 300 and 450 mg.
Drug: Open Label LAM-003
LAM-003
Maximum Tolerated Dose (MTD)
A primary objective was to determine the LAM-003 MTD and/or recommended dosing regimen (RDR) based on the pattern of dose-limiting toxicities (DLTs) in Cycle 1 of therapy. MTD as determined by DLTs.
Time frame: At the end of the 28-day observation period for Cycle 1.
Adverse Event Assessment
Number and percentage of participants with an adverse event (AE).
Time frame: Weekly during the first 4 weeks and then every 4 weeks for up to 48 weeks.
Maximum Plasma Concentration (Cmax)
The pharmacokinetic parameter Cmax was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug)
Time frame: Cycle 1 Days 1, 2 and 8 (1 cycle = 28 days)
Time of Maximum Concentration [Tmax]
The pharmacokinetic parameter Tmax was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug)
Time frame: Cycle 1 Days 1, 2 and 8 (1 cycle = 28 days)
Area Under the Curve [AUC]
The pharmacokinetic parameter area under the concentration-time curve was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug). AUClast is the area under the concentration-time curve from time-zero to the time of the last quantifiable concentration. AUCtau is the area under the concentration-time curve during the dosing interval where tau=24hours for once daily (QD) dosing. AUCtau was not calculated for LAM-003.
Time frame: Cycle 1 Days 1, 2 and 8 (1 cycle = 28 days)
Objective Response Rate
Tumor response by AML response criteria (Cheson 2003).
Time frame: Every 8 to 12 weeks for up to 48 weeks.
Event-Free Survival (EFS) and Overall Survival (OS)
Event-free survival (EFS), defined as the interval from the start of study therapy to the earliest of the first documentation of disease relapse, disease progression, treatment failure (TF), or death from any cause. Overall survival (OS), defined as the interval from the start of study therapy to death from any cause.
Time frame: Every 8 to 12 weeks for up to 48 weeks.
This study was conducted by 6 investigators located in medical centers throughout the United States.
| Milestone | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD |
|---|---|---|---|---|
| Started | 6 | 3 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 3 | 4 | 4 |
| Withdrew: Aml relapse or progression | 2 | 1 | 2 | 2 |
| Withdrew: Treatment failure | 3 | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
A primary objective was to determine the LAM-003 MTD and/or recommended dosing regimen (RDR) based on the pattern of dose-limiting toxicities (DLTs) in Cycle 1 of therapy. MTD as determined by DLTs.
| DLTs | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD |
|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) | 0 | 0 | 0 | 0 |
Number and percentage of participants with an adverse event (AE).
| Participants | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD |
|---|---|---|---|---|
| With ≥1 AE | 6 | 3 | 4 | 4 |
| With ≥1 TEAE | 6 | 3 | 4 | 4 |
| With ≥1 study-drug-related TEAE | 3 | 2 | 1 | 2 |
| With ≥1 TEAE of Grade ≥3 | 5 | 3 | 4 | 3 |
| With ≥1 study-drug-related TEAE of Grade ≥3 | 0 | 0 | 0 | 0 |
| With ≥1 SAE | 3 | 3 | 3 | 2 |
| With ≥1 treatment-emergent SAE | 3 | 3 | 3 | 2 |
| With ≥1 study-drug-related treatment-emergent SAE | 0 | 0 | 0 | 0 |
| With ≥1 AESI | 0 | 0 | 0 | 0 |
| With AEs resulting in drug interruption of study drug | 0 | 0 | 1 | 0 |
| With AEs (other than AML progression) resulting in permanent discontinuation of study drug | 1 | 0 | 0 | 1 |
| With AEs resulting in death within 30 days from the last dose of study drug | 1 | 1 | 2 | 1 |
The pharmacokinetic parameter Cmax was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug)
| ng/mL | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD |
|---|---|---|---|---|
| LAM-003A Day 1 | 3550 ± 1860 | 8360 ± 2230 | 9170 | 8240 ± 3750 |
| LAM-003A Day 8 | 5000 ± 576 | 8360 ± 1150 | 8500 | 9620 ± 3810 |
| LAM-003 Day 1 | 0.560 ± 0.320 | 1.47 ± 1.28 | 2.71 | 1.83 ± 1.30 |
| LAM-003 Day 8 | 0.617 ± 0.220 | 1.08 ± 1.36 | 3.60 | 1.45 ± 1.43 |
The pharmacokinetic parameter Tmax was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug)
| hours | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD |
|---|---|---|---|---|
| LAM-003A for Day 1 | 3.80 (1.00 to 4.00) | 3.80 (1.80 to 4.00) | 4.10 (4.10 to 4.10) | 1.95 (1.90 to 23.3) |
| LAM-003A for Day 8 | 2.00 (1.80 to 4.00) | 4.00 (4.00 to 5.80) | 2.10 (2.10 to 2.10) | 1.95 (1.10 to 2.00) |
| LAM-003 for Day 1 | 1.00 (0.50 to 1.00) | 1.80 (0.80 to 2.00) | 0.50 (0.50 to 0.50) | 0.50 (0.40 to 1.00) |
| LAM-003 for Day 8 | 0.75 (0.50 to 1.00) | 1.10 (0.50 to 1.10) | 0.50 (0.50 to 0.50) | 1.10 (0.600 to 3.00) |
The pharmacokinetic parameter area under the concentration-time curve was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug). AUClast is the area under the concentration-time curve from time-zero to the time of the last quantifiable concentration. AUCtau is the area under the concentration-time curve during the dosing interval where tau=24hours for once daily (QD) dosing. AUCtau was not calculated for LAM-003.
| h*ng/mL | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD |
|---|---|---|---|---|
| LAM-003A AUClast for Day 1 | 43100 ± 23200 | 112000 ± 45100 | 131000 | 105000 ± 39800 |
| LAM-003A AUClast for Day 8 | 24400 ± 5680 | 53600 ± 10400 | 52800 | 56400 ± 18000 |
| LAM-003 AUClast for Day 1 | 0.287 ± 0.254 | 0.958 ± 0.745 | 1.72 | 0.935 ± 1.10 |
| LAM-003 AUClast for Day 8 | 0.383 ± 0.311 | 1.18 ± 1.84 | 0.90 | 0.833 ± 0.837 |
| LAM-003A AUCtau for Day 1 | 26000 ± 43900 | 113000 ± 46100 | 132000 | 110000 ± 47300 |
| LAM-003A AUCtau for Day 8 | 42300 ± 4840 | — | 113000 | 103000 ± 33900 |
Tumor response by AML response criteria (Cheson 2003).
| Participants | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD |
|---|---|---|---|---|
| CRc: Composite complete remission including participants with CR, CRMRD-, and CRi | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 0 | 0 | 0 |
| Treatment Failure | 3 | 1 | 2 | 3 |
| Disease Relapse or Progression | 2 | 2 | 2 | 1 |
| Nonevaluable | 1 | 0 | 0 | 0 |
Event-free survival (EFS), defined as the interval from the start of study therapy to the earliest of the first documentation of disease relapse, disease progression, treatment failure (TF), or death from any cause. Overall survival (OS), defined as the interval from the start of study therapy to death from any cause.
| months | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD |
|---|---|---|---|---|
| EFS | 0.6 (0.1 to 1.9) | 0.9 (0.7 to 1.2) | 1.8 (0.3 to 3.5) | 1.5 (0.6 to 2.9) |
| OS | 3 (0.3 to 3.2) | 5.1 (1.0 to 5.9) | 3.4 (0.8 to 5.5) | 3.1 (1.6 to 4.3) |
Collected over Adverse Events were collected from the signing of informed consent through to 30 days after the final dose of study drug administration or when any ongoing drug-related AEs and/or serious adverse events (SAEs) have resolved or become stable (up to Week 48).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LAM-003 200 mg QD | 2/6 (33.3%) | 3/6 (50%) | 6/6 (100%) |
| LAM-003 300 mg QD | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| LAM-003 450 mg QD | 2/4 (50%) | 3/4 (75%) | 4/4 (100%) |
| LAM-003 600 mg QD | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| LAM-003 750 mg QD | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | LAM-003 750 mg QD |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/6 | 1/3 | 0/4 | 0/4 | 2/3 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/6 | 2/3 | 1/4 | 0/4 | 0/3 |
| Disease ProgressionGeneral disorders | 1/6 | 1/3 | 2/4 | 1/4 | 0/3 |
| Cerebral HemorrhageNervous system disorders | 0/6 | 0/3 | 0/4 | 0/4 | 1/3 |
| Pneumonia bacterialInfections and infestations | 0/6 | 0/3 | 0/4 | 0/4 | 1/3 |
| Hemoglobin DecreasedInvestigations | 0/6 | 0/3 | 0/4 | 1/4 | 0/3 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/6 | 0/3 | 0/4 | 1/4 | 0/3 |
| WBC Count IncreasedInvestigations | 1/6 | 0/3 | 0/4 | 0/4 | 0/3 |
| Hemorrhage IntracranialNervous system disorders | 1/6 | 0/3 | 0/4 | 0/4 | 0/3 |
| Event | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | LAM-003 750 mg QD |
|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 1/6 | 3/3 | 0/4 | 1/4 | 1/3 |
| Oedma peripheralGeneral disorders | 3/6 | 2/3 | 0/4 | 1/4 | 1/3 |
| ChillsGeneral disorders | 1/6 | 2/3 | 1/4 | 1/4 | 0/3 |
| Non-cardiac chest painGeneral disorders | 0/6 | 2/3 | 1/4 | 0/4 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 3/6 | 1/3 | 1/4 | 0/4 | 2/3 |
| VomitingGastrointestinal disorders | 1/6 | 2/3 | 1/4 | 1/4 | 1/3 |
| Platelet count decreasedInvestigations | 4/6 | 0/3 | 1/4 | 0/4 | 0/3 |
| White blood cell count increasedInvestigations | 4/6 | 0/3 | 0/4 | 0/4 | 0/3 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/6 | 2/3 | 1/4 | 1/4 | 2/3 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/6 | 2/3 | 1/4 | 1/4 | 0/3 |
The study population was generally consistent with the epidemiology of AML.
| Age, Continuous(years) | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | Total |
|---|---|---|---|---|---|
| Median | 71 (39 to 82) | 34 (26 to 65) | 75 (54 to 83) | 67.5 (48 to 73) | 68 (26 to 83) |
| Sex: Female, Male(Participants) | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | Total |
|---|---|---|---|---|---|
| Female | 2 | 1 | 2 | 1 | 6 |
| Male | 4 | 2 | 2 | 3 | 11 |
| Ethnicity (NIH/OMB)(Participants) | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 1 | 3 |
| Not Hispanic or Latino | 4 | 3 | 4 | 3 | 14 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 2 | 4 | 4 | 13 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 0 | 0 | 3 |
| Region of Enrollment(Participants) | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | Total |
|---|---|---|---|---|---|
| United States | 6 | 3 | 4 | 4 | 17 |
| BMI(kg/m^2) | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | Total |
|---|---|---|---|---|---|
| Median | 32.4 (19 to 45) | 27.6 (26 to 29) | 27.5 (24 to 28) | 21.6 (20 to 48) | 27.6 (19 to 48) |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | Total |
|---|---|---|---|---|---|
| 0 = Fully active | 0 | 0 | 0 | 1 | 1 |
| 1 = Restricted in physically strenuous activity but ambulatory | 5 | 2 | 1 | 2 | 10 |
| 2 = Ambulatory and capable of all self-care but unable to carry out any work activities | 1 | 1 | 3 | 1 | 6 |
| Elevated peripheral blood AML blast %(percentage) | LAM-003 200 mg QD | LAM-003 300 mg QD | LAM-003 450 mg QD | LAM-003 600 mg QD | Total |
|---|---|---|---|---|---|
| Median | 24.75 (2.9 to 89.3) | 41.40 (13.6 to 95.1) | 22.15 (11.9 to 74.0) | 34.05 (4.5 to 97.1) | 30.40 (2.9 to 97.1) |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Feb 2020, 25 months.
Results were first posted in May 2024, 4 years 2 months after primary completion.
Of 182 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 25 months is below that.
Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OrphAI Therapeutics